Stanford type B aortic dissection patients with normally hypotensive medical therapy and pitavastatin treatment effect.

Stanford type B aortic dissection patients with normally hypotensive medical therapy and pitavastatin treatment effect. - Stanford type B aortic dissection patients with pitavastatin treatment trial (STANP trial)

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000000685

Enrollment

100

Registered

2007-06-01

Start date

2007-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stanford type B acute aortic dissection patients transported within 48 hours of symptom onset , adaptable normally hypotensive medical therapy.

Interventions

Standard hypotensive medical therapy with pitavastatin 2 mg daily for a period of 12 months Standard hypotensive medical therapy for a period of 12 months

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) Stanford type B acute aortic dissection patients transported within 48 hours after onset. (2) Standard hypotensive medical therapy (3) Greater than 20 years old at time of consent. (4) Provide voluntary written informed consent for participation in the study after being fully informed.

Exclusion criteria

Exclusion criteria: (1) Patients with the total diameter of descending aorta (minor axis) by CT angiography more than 50mm. (2) Marfan's syndrome patients (3) Patients with continuous pain. (4) Patients with unstable vital signs. (5) Patients with signs or symptoms of organ ischemia (6) Fasting serum levels of TC >/= 250 mg/dL. (7) Known hypersensitivity or history of clinically significant adverse reactions to any component of study drugs. (8) Patients with hepatopathy (ALT >/=100 IU/L) or biliary obstruction with the following conditions - acute hepatitis, acute exacerbation of chronic hepatitis, hepatic cirrhosis, hepatoma, jaundice. (9) Pregnant, possibly pregnant, or lactating. (10) Patients with significant renal dysfunction (serum creatinine >/= 2.0 mg/dL) or renal dialysis. (11) Patient who is judged by the investigator to be inappropriate for inclusion in the study.

Design outcomes

Primary

Measure	Time frame
Percent change and absolute change in the total diameter of the descending aorta (minor axis) by CT angiography	—

Secondary

Measure	Time frame
Percent change and absolute change in the following items (1)Threatened rupture (2)Surgical operation (3)Serum lipid profile (LDL-C, triglyceride, HDL-C) (4)Serum creatinine (5)Correlation with the total diameter of descending aorta (minor axis) and serum lipid profile or serum creatinine (6)All-cause mortalities (7)Evaluation of adverse events (8)Laboratory test abnormalities	—

Countries

Japan

Contacts

Public ContactNaotaka Motoyoshi

STANP trial staff Cardiovascular Surgery, Tohoku University, Graduate School of Medicine

motoyoshi_n810@yahoo.co.jp022-717-7222

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026